Publications by authors named "S Tarantolo"

Claim this Profile
D
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Stefano Tarantolo

Blood Cancer J· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Ruben Niesvizky, Ashraf Z Badros, Luciano J Costa, Scott A Ely, Seema B Singhal, Stefano Tarantolo

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological effects and therapeutic role of C5a in cancer.
Victoria R Darling, Ralph J Hauke, Stefano Tarantolo, Devendra K Agrawal

Expert Rev Clin Immunol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Ajay K Gopal, Stefano R Tarantolo, Naresh Bellam, Damian J Green, Melissa Griffin

Invest New Drugs· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT).
J A Steuter, M L H Villanueva, F R Loberiza, J O Armitage, R G Bociek, S R Tarantolo

Bone Marrow Transplant· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis